Bank of New York Mellon Corp - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 341 filers reported holding NEKTAR THERAPEUTICS in Q2 2019. The put-call ratio across all filers is 2.70 and the average weighting 0.1%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2023$52,567
-27.6%
88,259
-30.1%
0.00%
Q2 2023$72,589
-93.5%
126,197
-92.1%
0.00%
Q1 2023$1,121,976
-69.6%
1,596,210
-2.2%
0.00%
-100.0%
Q4 2022$3,686,953
-33.0%
1,631,395
-5.1%
0.00%0.0%
Q3 2022$5,502,000
-14.3%
1,719,478
+1.8%
0.00%0.0%
Q2 2022$6,419,000
-33.5%
1,689,163
-5.7%
0.00%
-50.0%
Q1 2022$9,652,000
-58.0%
1,790,742
+5.2%
0.00%
-50.0%
Q4 2021$23,003,000
-25.5%
1,702,700
-0.9%
0.00%
-33.3%
Q3 2021$30,863,000
+4.0%
1,718,385
-0.6%
0.01%0.0%
Q2 2021$29,665,000
-13.9%
1,728,702
+0.4%
0.01%
-14.3%
Q1 2021$34,440,000
+16.9%
1,722,058
-0.6%
0.01%
+16.7%
Q4 2020$29,463,000
-0.9%
1,733,073
-3.3%
0.01%
-14.3%
Q3 2020$29,733,000
-30.9%
1,792,202
-3.5%
0.01%
-36.4%
Q2 2020$43,030,000
+33.9%
1,857,924
+3.2%
0.01%0.0%
Q1 2020$32,138,000
-18.7%
1,800,467
-1.7%
0.01%
+10.0%
Q4 2019$39,529,000
+46.1%
1,831,292
+23.3%
0.01%
+42.9%
Q3 2019$27,052,000
-48.6%
1,485,169
+0.4%
0.01%
-50.0%
Q2 2019$52,637,000
+8.5%
1,479,386
+2.4%
0.01%0.0%
Q1 2019$48,526,000
+4.1%
1,444,210
+1.8%
0.01%
-6.7%
Q4 2018$46,634,000
-45.4%
1,418,699
+1.3%
0.02%
-31.8%
Q3 2018$85,406,000
+50.8%
1,401,029
+20.8%
0.02%
+46.7%
Q2 2018$56,639,000
-58.6%
1,159,918
-10.0%
0.02%
-60.5%
Q1 2018$136,924,000
+16.1%
1,288,568
-34.8%
0.04%
+22.6%
Q4 2017$117,939,000
+138.3%
1,974,858
-4.2%
0.03%
+121.4%
Q3 2017$49,493,000
+18.4%
2,062,186
-3.6%
0.01%
+16.7%
Q2 2017$41,812,000
-16.2%
2,138,632
+0.6%
0.01%
-14.3%
Q1 2017$49,895,000
+107.6%
2,125,902
+8.5%
0.01%
+100.0%
Q4 2016$24,032,000
-23.4%
1,958,602
+7.3%
0.01%
-22.2%
Q3 2016$31,355,000
+24.6%
1,825,071
+3.2%
0.01%
+12.5%
Q2 2016$25,173,000
-4.6%
1,768,992
-7.8%
0.01%0.0%
Q1 2016$26,379,000
-16.3%
1,918,587
+2.6%
0.01%
-20.0%
Q4 2015$31,499,000
+61.2%
1,869,414
+4.9%
0.01%
+66.7%
Q3 2015$19,537,000
+5.5%
1,782,546
+20.4%
0.01%
+20.0%
Q2 2015$18,527,000
-31.9%
1,480,958
-40.1%
0.01%
-28.6%
Q1 2015$27,218,000
-48.8%
2,474,410
-27.8%
0.01%
-50.0%
Q4 2014$53,124,000
+24.0%
3,427,329
-3.4%
0.01%
+16.7%
Q3 2014$42,841,000
-52.9%
3,549,480
-50.0%
0.01%0.0%
Q2 2014$90,944,000
+114.8%
7,093,794
+103.1%
0.01%0.0%
Q1 2014$42,341,000
+10.8%
3,493,536
+3.8%
0.01%
+9.1%
Q4 2013$38,199,000
-29.8%
3,365,468
-35.4%
0.01%
+37.5%
Q3 2013$54,378,000
+57.7%
5,206,108
+74.4%
0.01%
-27.3%
Q2 2013$34,473,0002,984,7220.01%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q2 2019
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 432,952$1,385,0000.91%
GREAT POINT PARTNERS LLC 447,820$1,433,0000.34%
Birchview Capital, LP 128,000$410,0000.29%
Edgestream Partners, L.P. 1,047,636$3,352,0000.26%
Rhenman & Partners Asset Management AB 550,000$2,068,0000.22%
CM Management, LLC 50,000$160,0000.18%
TANG CAPITAL MANAGEMENT LLC 430,037$1,376,0000.17%
PDT Partners, LLC 307,953$985,0000.15%
Virtus ETF Advisers LLC 72,018$230,0000.09%
ALGERT GLOBAL LLC 476,412$1,525,0000.09%
View complete list of NEKTAR THERAPEUTICS shareholders